Anticancer and radiosensitizing evaluation of some new pyranothiazole-Schiff bases bearing the biologically active sulfonamide moiety

The present work reports the synthesis of some new Schiff bases, 5-(substituted benzylideneamino)-6-cyano-7H-7-(4-methoxyphenyl)-2-(4-sulphamoylphenylamino) pyrano[2,3-d]thiazole (5–15). The design of the structures of these compounds complies with the general pharmacophoric requirements for CA inhibiting anticancer drugs. The newly synthesized compounds were evaluated for their in vitro anticancer activity against human breast cancer cell line (MCF7). Most of the screened compounds showed interesting cytotoxic activities compared to doxorubicin as a reference drug. Compounds 4, 6–8 and 11 (IC50: 27.51, 10.25, 9.55, 9.39 and 9.70 μM, respectively) exhibited higher cytotoxic activities than the reference drug doxorubicin (IC50: 32.00 μM). Additionally, the previously mentioned compounds were evaluated again for their ability to enhance the cell killing effect of γ-radiation.

This work reports the synthesis of new Schiff bases, 5-(substituted benzylideneamino)-6-cyano-7H-7-(4-methoxyphenyl)-2-(4-sulphamoylphenylamino) pyrano[2,3-d]thiazole. Five compounds exhibited higher cytotoxic activities than the reference drug doxorubicin and enhanced the cell killing effect of γ-radiation.Figure optionsDownload as PowerPoint slideHighlights
► Synthesis of Schiff bases of sulphamoylphenylamino-pyrano[2,3-d]thiazole.
► The structure-design of these compounds complies with pharmacophoric requirements for CA inhibiting anticancer drugs.
► Five compounds exhibited higher cytotoxic activities than the reference drug doxorubicin.
► These five compounds were evaluated again for their ability to enhance the cell killing effect of γ-radiation.